Hims blames drugmakers for high GLP-1 prices in Super Bowl TV spot: It’s a bold—and expensive—move for Hims, especially considering the uncertain future of compounded weight loss drugs and doctors’ growing apprehension of how these treatments are marketed and sold.
Consumers’ vaccine skepticism persists: Their growing distrust coupled with the spectre of RFK Jr. leading the HHS could portend bad news for Big Pharma
Neko Health secures $260M in Series B funding: The medical scanning startup is now valued at $1.8 billion, which feels overblown when you take consumers’ appetite for the service and ability to afford it into account.
On today’s podcast episode, we discuss the trend of healthcare and pharmaceutical brands selling prescription drugs, treatments, and medical services directly to consumers and how rising medical costs are changing patients’ relationship with the healthcare system. Tune in to the conversation with Senior Director of Podcasts and host Marcus Johnson, and Senior Analysts Dane Finley and Rajiv Leventhal. Listen everywhere and watch on YouTube and Spotify.
US hospitals use predictive AI tools, but many use biased data: Most AI models make recommendations based on homogenous data samples, which could actually harm many patients. But more regulatory oversight of healthcare AI isn’t guaranteed to happen in the near term.
Instagram, Facebook suppress content from abortion pill providers: The platforms are walking a tightrope between enforcing their community guidelines and alienating healthcare brands and patients.
Investments in women’s health startups are alarmingly low: Yet startups addressing conditions such as menopause have seen success when VC funding has gone their way, showing that investments in the space have a high potential for viable returns.
Gen Z struggles to manage health and wellness: They understand the importance of taking health into their own hands but fail to deliver good results. We explore how healthcare marketers, providers, and insurers can arm this generation with the necessary support.
Google DeepMind expects AI-designed drug trials to start this year: While the jury is out on how effective the tech is at accelerating drug discovery, that hasn’t stopped pharma companies from pursuing tie-ups with the firm to do just that.
Sanofi’s Opella secures FDA nod to pursue OTC Cialis study: If Cialis’ shift from a prescription drug to over-the-counter product comes to fruition, both consumers and D2C retailers could benefit.
It’s about to get a lot harder to get cheap GLP-1s: Rising costs may force consumers to cut back on discretionary spending, creating headwinds for retailers already fearing tariff-driven cost increases.
Cancer patients are getting younger: Healthcare marketers can make preventive screening guidance less complicated for patients. We explore how.
Trump signs order for the US to leave the World Health Organization: The decision could turn into a public health nightmare for the US, while also impeding health initiatives worldwide.
CMS unveils list of drugs for the next round of Medicare price negotiations: Drugmakers’ efforts to win over the Trump administration could amend the process in their favor—up to a certain point.
President-elect Donald Trump's second term promises profound shifts across commerce, technology, and regulation that will reshape how businesses operate and consumers behave. As the president-elect prepares to take office, his policy priorities are already triggering market reactions and pivots from major corporations.
UnitedHealth Group’s shares fall after mixed Q4 earnings: While the healthcare titan will have to contend with potential changes to how its pharmacy benefit manager does business, its reaffirmed outlook for 2025 suggests it’s not too concerned.
What a TikTok ban means for healthcare and pharma: Health influencers, marketers, and patients have all gravitated toward TikTok in recent years. We examine the implications of a ban on each.
Consumers want AI that’s vetted by doctors: They believe the tech can improve their experience, but only if it’s been responsibly implemented and its conclusions verified by a human clinician.
Drugmakers will push Trump to delay Medicare price negotiations: We believe the drug price negotiation program is well-intended given how much Medicare and US consumers pay for certain medications. While a program reversal is unlikely, we’ll find out soon what the Trump administration thinks.
Doctors’ ethics ratings slip: We explore what’s driving the decline in this new data, and examine how trust in physicians can be rebuilt.